Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens (Q82481907)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

L R Stanberry

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

J K Simon

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

C Johnson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

P L Robinson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

J Morry

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

M R Flack

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

S Gracon

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

A Myc

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

T Hamouda

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

J R Baker

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

8 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

307-316

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

Vaccination strategies to promote mucosal antibody responses.

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Mucosal immunity: induction, dissemination, and effector functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

A novel, killed-virus nasal vaccinia virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

The role of M cells of human nasopharyngeal lymphoid tissue in influenza virus sampling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

The global impact of influenza on morbidity and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Influenza and the rates of hospitalization for respiratory disease among infants and young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Epidemiology of influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Safety and immunogenicity of a Proteosome™-trivalent inactivated influenza vaccine, given nasally to healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Mucosal antibody response induced with a nasal virosome-based influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Intranasal Influenza Vaccine in a Working Population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Human immune responses to influenza virus vaccines administered by systemic or mucosal routes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Evaluation of the Cohort Size in Phase I Dose Escalation Trials Based on Laboratory Data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Do multiple outcome measures require p-value adjustment?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.094

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.10.094

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22079079%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference